BioMarin Pharmaceutical Down 22.4% Since SmarTrend Downtrend Call (BMRN)
Comtex SmarTrend(R) - Tue May 13, 11:11AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 2 months, BioMarin Pharmaceutical has returned 22.39% as of today's recent price of $58.75.
Post Earnings Update: BioMarin Pharmaceutical Has Sunk 2.9% Lower in Past Week (BMRN)
Comtex SmarTrend(R) - Mon May 12, 11:36AM CDT
When BioMarin Pharmaceutical (NASDAQ:BMRN) reported earnings 11 days ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.18 on sales of $145.3 million. The company actually reported a loss of $0.01 per share on sales of $151.6 million, beating EPS estimates by $0.17 and beating revenue estimates by $6.2 million. Shares of BioMarin Pharmaceutical have slipped from $60.31 to $58.54, representing a loss of 2.9%, since the company reported earnings 11 days ago.
'Mad Money' Lightning Round: BioMarin Is for Real
at The Street - Thu May 08, 5:00AM CDT
Cramer has moved on from Vale, wants you to stick with Alcatel-Lucent and likes SandRidge Energy over Abraxas Petroleum.
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Jim Cramer's 'Mad Money' Recap: A Market Divided
at The Street - Wed May 07, 7:12PM CDT
Cramer warns investors must use caution until a clear direction appears.
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex
PR Newswire - Wed May 07, 7:29AM CDT
Today, Analysts Review released its analysts' notes regarding Discover Financial Services (NYSE: DFS), BlackRock, Inc. (NYSE: BLK), Covance Inc. (NYSE: CVD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2142-100free.
BioMarin Pharmaceutical Shares Down 20.9% Since SmarTrend's Sell Call (BMRN)
Comtex SmarTrend(R) - Tue May 06, 9:56AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 2 months, BioMarin Pharmaceutical has returned 20.87% as of today's recent price of $59.90.
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th
GlobeNewswire - Tue May 06, 9:15AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on Wednesday, May 14 at 4:20pm PT and Jean-Jacques Bienaime, Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 20 at 8:00am ET.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Loss at BioMarin Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 3:00PM CDT
Higher product sales narrowed first quarter loss at BioMarin (BMRN).
BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 5:12PM CDT
Ultra-rare disease fighting biotech BioMarin Pharmaceutical proved in its first-quarter results after the bell that there's certainly growth to be had in developing therapies that treat rare diseases. For the quarter, BioMarin reported a revenue...
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 3.57% Rise
Comtex SmarTrend(R) - Thu May 01, 4:31PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $57.02 to a high of $61.05. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $58.94 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress
GlobeNewswire - Thu May 01, 3:11PM CDT
- Total BioMarin Revenue Grew 18.5% in 1Q14
Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics I
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:30AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for BioMarin , InterMune , and Seattle Genetics . BioMarin will hold an earnings call after the bell today Orphan drug specialist BioMarin will report...
Better Biotech Buy: Vertex Pharmaceuticals Incorporated vs. BioMarin Pharmaceutical Inc.
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Orphan drugs, treatments for rare and ultra-rare diseases that have traditionally lacked reliable medicines, have become big business in biotech and pharmaceuticals. Alexion Pharmaceuticals ' Soliris might be the most well-known example of a single...
BioMarin wins VIMIZIM's marketing approval in the EU for treating Morquio A Syndrome in all ages
M2 - Tue Apr 29, 5:39AM CDT
Biopharmaceutical company BioMarin Pharmaceutical (NasdaqGS:BMRN) disclosed on Monday the receipt of European Commission's marketing authorisation for VIMIZIM (elosulfase alfa), the first specific treatment approved in the EU for Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) in patients of all ages.
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages
GlobeNewswire - Mon Apr 28, 10:07AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission has granted marketing authorization for VIMIZIM(R) (elosulfase alfa), the first specific treatment approved in the European Union for Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) in patients of all ages. As the first drug ever approved for Morquio A syndrome, VIMIZIM has been granted orphan drug status in the European Union, which confers ten years of market exclusivity.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia